LncRNA FEZF1-AS1 Facilitates Cisplatin Resistance in Non-small Cell Lung Cancer Through Modulating the MiR-32-5p-glutaminase Axis

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2024 Jul 15

PMID 39005663

Authors

Wei Lin

Wei-Chun Wu

Zhi Liang

Jian-Hao Zhang

Shi-Peng Fang

Affiliations

Soon will be listed here.

Abstract

Non-small cell lung cancer (NSCLC) is one of the prevalent malignancies. Cisplatin (CDDP) is a conventional chemotherapeutic agent against NSCLC. However, inherent and acquired chemoresistance limited the effectiveness of cisplatin in treatment of NSCLC. This study aimed to investigate the roles and underlying mechanisms of lncRNA-FEZF1-AS1 in mediating cisplatin sensitivity in NSCLC. We found that FEZF1-AS1 levels were significantly higher in lung cancer patients and cell lines. Blocking FEZF1-AS1 sensitized lung cancer cells to cisplatin. Additionally, both glutamine metabolism and FEZF1-AS1 were significantly elevated in cisplatin resistant NSCLC cell lines, A549/CDDP R and SK-MES-1 CDDP/R. Analysis using bioinformatics, RNA pull-down assay and luciferase assay demonstrated that FEZF1-AS1 sponged miR-32-5p, which acted as a tumor suppressor in NSCLC. Glutaminase (GLS), a key enzyme in the glutamine metabolism, was predicted and validated as the direct target of miR-32-5p in NSCLC cells. Inhibiting glutamine metabolism or reducing glutamine supply effectively resensitized cisplatin-resistant cells. Furthermore, restoring miR-32-5p in FEZF1-AS1-overexpressing cisplatin resistant cells successfully overcame FEZF1-AS1-mediated cisplatin resistance by targeting GLS. These findings were further supported by xenograft mice experiments. This study uncovered the roles and molecular mechanisms of lncRNA FEZF1-AS1 in mediating cisplatin resistance in NSCLC, specifically through modulating the miR-32-5p-GLS axis, providing support for the development of new therapeutic approaches against chemoresistant lung cancer.

References

Zhu L, Zhu X, Wu Y . Effects of Glucose Metabolism, Lipid Metabolism, and Glutamine Metabolism on Tumor Microenvironment and Clinical Implications. Biomolecules. 2022; 12(4). PMC: 9028125. DOI: 10.3390/biom12040580. View

Hui Y, Yang Y, Li D, Wang J, Di M, Zhang S . LncRNA FEZF1-AS1 Modulates Cancer Stem Cell Properties of Human Gastric Cancer Through miR-363-3p/HMGA2. Cell Transplant. 2020; 29:963689720925059. PMC: 7563941. DOI: 10.1177/0963689720925059. View

Song H, Li H, Ding X, Li M, Shen H, Li Y . Long non‑coding RNA FEZF1‑AS1 facilitates non‑small cell lung cancer progression via the ITGA11/miR‑516b‑5p axis. Int J Oncol. 2020; 57(6):1333-1347. PMC: 7646599. DOI: 10.3892/ijo.2020.5142. View

Yu M, Qi B, Xiaoxiang W, Xu J, Liu X . Baicalein increases cisplatin sensitivity of A549 lung adenocarcinoma cells via PI3K/Akt/NF-κB pathway. Biomed Pharmacother. 2017; 90:677-685. DOI: 10.1016/j.biopha.2017.04.001. View

Pavlova N, Zhu J, Thompson C . The hallmarks of cancer metabolism: Still emerging. Cell Metab. 2022; 34(3):355-377. PMC: 8891094. DOI: 10.1016/j.cmet.2022.01.007. View

Liu H, Zhang H, Liu M, Li H, Wang X, Wang M . GLS1 depletion inhibited colorectal cancer proliferation and migration via redox/Nrf2/autophagy-dependent pathway. Arch Biochem Biophys. 2021; 708:108964. DOI: 10.1016/j.abb.2021.108964. View

Ma B, Wang S, Wu W, Shan P, Chen Y, Meng J . Mechanisms of circRNA/lncRNA-miRNA interactions and applications in disease and drug research. Biomed Pharmacother. 2023; 162:114672. DOI: 10.1016/j.biopha.2023.114672. View

Sun Z, Gao S, Xuan L, Liu X . Long non-coding RNA FEZF1-AS1 induced progression of ovarian cancer via regulating miR-130a-5p/SOX4 axis. J Cell Mol Med. 2020; 24(7):4275-4285. PMC: 7171310. DOI: 10.1111/jcmm.15088. View

Adams S, Stone E, Baldwin D, Vliegenthart R, Lee P, Fintelmann F . Lung cancer screening. Lancet. 2022; 401(10374):390-408. DOI: 10.1016/S0140-6736(22)01694-4. View

10.

Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O . Molecular mechanisms of cisplatin resistance. Oncogene. 2011; 31(15):1869-83. DOI: 10.1038/onc.2011.384. View

11.

Statello L, Guo C, Chen L, Huarte M . Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2020; 22(2):96-118. PMC: 7754182. DOI: 10.1038/s41580-020-00315-9. View

12.

Zhang T, Yu S, Zhao S . LncRNA FEZF1-AS1 promotes colorectal cancer progression through regulating the miR-363-3p/PRRX1 pathway. Adv Clin Exp Med. 2021; 30(8):839-848. DOI: 10.17219/acem/135693. View

13.

Ying L, Wang J, Feng J, Wu Z . Long non-coding RNA SNHG17 contributes to the progression of pancreatic adenocarcinoma by modulating miR-32-5p/EZH2/STAT3 signaling. Mol Biol Rep. 2023; 50(7):5941-5947. DOI: 10.1007/s11033-023-08530-1. View

14.

Dong J, Geng J, Tan W . MiR-363-3p suppresses tumor growth and metastasis of colorectal cancer via targeting SphK2. Biomed Pharmacother. 2018; 105:922-931. DOI: 10.1016/j.biopha.2018.06.052. View

15.

Alduais Y, Zhang H, Fan F, Chen J, Chen B . Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment. Medicine (Baltimore). 2023; 102(8):e32899. PMC: 11309591. DOI: 10.1097/MD.0000000000032899. View

16.

Liang M, Li Y, Dai T, Chen C . lncRNA FEZF1-AS1 regulates biological behaviors of cervical cancer by targeting miRNA-1254. Food Sci Nutr. 2021; 9(9):4722-4737. PMC: 8441442. DOI: 10.1002/fsn3.2315. View

17.

Hou X, Zhang Z, Cao X, Wang X . Long noncoding RNAs, glucose metabolism and cancer (Review). Oncol Lett. 2023; 26(2):340. PMC: 10326653. DOI: 10.3892/ol.2023.13925. View

18.

Liu W, Ning J, Li C, Hu J, Meng Q, Lu H . Overexpression of Sphk2 is associated with gefitinib resistance in non-small cell lung cancer. Tumour Biol. 2015; 37(5):6331-6. DOI: 10.1007/s13277-015-4480-1. View

19.

Yuan P, Tang C, Chen B, Lei P, Song J, Xin G . miR‑32‑5p suppresses the proliferation and migration of pancreatic adenocarcinoma cells by targeting TLDC1. Mol Med Rep. 2021; 24(5). PMC: 8430301. DOI: 10.3892/mmr.2021.12392. View

20.

Imyanitov E, Iyevleva A, Levchenko E . Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives. Crit Rev Oncol Hematol. 2020; 157:103194. DOI: 10.1016/j.critrevonc.2020.103194. View